Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 72; no. 6; pp. 1036 - 1038
Main Authors Kim, Seoyoung C., Sarpatwari, Ameet, Landon, Joan E., Desai, Rishi J.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.06.2020
Subjects
Immunotherapy
Infliximab
Monoclonal antibodies
Necrosis
TNF inhibitors
Tumor necrosis factor-α
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2326-5191
2326-5205
DOI:10.1002/art.41201